[Cardiotoxicity of anthracyclines in children. Contribution of anthracyclines in pediatric oncology].
Anthracyclines induced cardiotoxicity in children remains a major problem. Classical data are found: cumulative dose, way of injection, anterior cardiopathy, cardiac area irradiation, interaction with other cytotoxic drugs ad age. 2 kinds of disorders are recorded: 1) Acute rhythmic dysfunctions, early and often transitory; 2) congestive heart failure often not reversible and depending on total dose. Prognostic is still poor and intricate with prognostic of the tumor. Over all incidence is 2.7%. Very young children seem to be more sensitive. Continuous infusion is less toxic than IV bolus. Studies with new anthracyclines are yet uncommon but seems to be comparative with adult literature. Monitoring is identical to adults. EKG is of minor interest. Endomyocardial biopsies have been reported. There is no prognostic value of ultrasound tomogram, but exercise echocardiography can be performed. Nuclide fraction ejection is more reliable.
D000293:Adolescent; D009202:Cardiomyopathies / Q000139:chemically induced; D002648:Child; D002675:Child, Preschool; D003630:Daunorubicin / Q000009:adverse effects*; D004317:Doxorubicin / Q000009:adverse effects*; D006321:Heart / Q000187:drug effects*; D006331:Heart Diseases / Q000139:chemically induced* / Q000517:prevention & control; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D010493:Pericarditis / Q000139:chemically induced
D004317:Doxorubicin; D003630:Daunorubicin
Cardiotoxicité des anthracyclines chez l'enfant. Apport des nouvelles anthracyclines en oncologie pédiatrique.